Dramatic efficacy of cannabidiol on refractory chronic pain in an adolescent with sickle cell disease
Lara Mayrand 1 2 3, Anne-Laure Tarbé de Saint Hardouin 3, Thiago Trovati Maciel 1 4, Rachel Rignault-Bricard 1 4, Melissa Taylor 2 4, Joséphine Brice 2 4, Mariane de Montalembert 2 4, Olivier Hermine 1 4 5 6, Céline Greco 1 3, Slimane Allali 1 2 4
- 1Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm U1163, Université Paris Cité, Paris, France.
- 2Department of General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker-Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
- 3Department of Pain and Palliative Care Unit, Necker-Enfants Malades Hospital, AP-HP, Université Paris Cité, Paris, France.
- 4Laboratory of Excellence GR-Ex, Paris, France.
- 5Department of Hematology, Necker-Enfants Malades Hospital, AP-HP, Université Paris Cité, Paris, France.
- 6Reference Center for Mastocytosis, Necker-Enfants Malades Hospital, AP-HP, Paris, France.
Affiliationer
Here, we report a dramatic efficacy of cannabidiol in an adolescent with SCD suffering from chronic pain refractory to other analgesics, with complete regression of chronic pain and rapid plasma histamine level normalization after treatment.
